Logo image of ZYME

ZYMEWORKS INC (ZYME) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ZYME - US98985Y1082 - Common Stock

24.02 USD
+0.2 (+0.84%)
Last: 11/21/2025, 8:06:49 PM
24.71 USD
+0.69 (+2.87%)
After Hours: 11/21/2025, 8:06:49 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to ZYME. ZYME was compared to 533 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ZYME as it has an excellent financial health rating, but there are worries on the profitability. ZYME shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ZYME has reported negative net income.
ZYME had a negative operating cash flow in the past year.
ZYME had negative earnings in 4 of the past 5 years.
ZYME had negative operating cash flow in 4 of the past 5 years.
ZYME Yearly Net Income VS EBIT VS OCF VS FCFZYME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

ZYME's Return On Assets of -15.97% is amongst the best of the industry. ZYME outperforms 80.19% of its industry peers.
ZYME has a better Return On Equity (-19.82%) than 84.30% of its industry peers.
Industry RankSector Rank
ROA -15.97%
ROE -19.82%
ROIC N/A
ROA(3y)-9.25%
ROA(5y)-23.15%
ROE(3y)-12.18%
ROE(5y)-33.12%
ROIC(3y)N/A
ROIC(5y)N/A
ZYME Yearly ROA, ROE, ROICZYME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80 -100

1.3 Margins

ZYME does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZYME Yearly Profit, Operating, Gross MarginsZYME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

8

2. Health

2.1 Basic Checks

ZYME does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZYME has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, ZYME has more shares outstanding
ZYME has a better debt/assets ratio than last year.
ZYME Yearly Shares OutstandingZYME Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ZYME Yearly Total Debt VS Total AssetsZYME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

ZYME has an Altman-Z score of 11.35. This indicates that ZYME is financially healthy and has little risk of bankruptcy at the moment.
ZYME has a Altman-Z score of 11.35. This is amongst the best in the industry. ZYME outperforms 84.30% of its industry peers.
There is no outstanding debt for ZYME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.35
ROIC/WACCN/A
WACC8.7%
ZYME Yearly LT Debt VS Equity VS FCFZYME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 6.94 indicates that ZYME has no problem at all paying its short term obligations.
The Current ratio of ZYME (6.94) is better than 70.28% of its industry peers.
A Quick Ratio of 6.94 indicates that ZYME has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.94, ZYME is in the better half of the industry, outperforming 70.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.94
Quick Ratio 6.94
ZYME Yearly Current Assets VS Current LiabilitesZYME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

7

3. Growth

3.1 Past

ZYME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.37%, which is quite impressive.
ZYME shows a strong growth in Revenue. In the last year, the Revenue has grown by 116.21%.
The Revenue has been growing by 20.93% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)34.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)116.21%
Revenue growth 3Y41.91%
Revenue growth 5Y20.93%
Sales Q2Q%72.59%

3.2 Future

ZYME is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.53% yearly.
Based on estimates for the next years, ZYME will show a very strong growth in Revenue. The Revenue will grow by 33.42% on average per year.
EPS Next Y36.42%
EPS Next 2Y44.73%
EPS Next 3Y31.63%
EPS Next 5Y17.53%
Revenue Next Year66.87%
Revenue Next 2Y62.13%
Revenue Next 3Y33.15%
Revenue Next 5Y33.42%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ZYME Yearly Revenue VS EstimatesZYME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
ZYME Yearly EPS VS EstimatesZYME Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ZYME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
ZYME is valuated quite expensively with a Price/Forward Earnings ratio of 182.41.
Based on the Price/Forward Earnings ratio, ZYME is valued cheaper than 86.92% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ZYME to the average of the S&P500 Index (34.42), we can say ZYME is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 182.41
ZYME Price Earnings VS Forward Price EarningsZYME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZYME Per share dataZYME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ZYME does not grow enough to justify the current Price/Earnings ratio.
ZYME's earnings are expected to grow with 31.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.73%
EPS Next 3Y31.63%

More info and screens

0

5. Dividend

5.1 Amount

ZYME does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZYMEWORKS INC

NASDAQ:ZYME (11/21/2025, 8:06:49 PM)

After market: 24.71 +0.69 (+2.87%)

24.02

+0.2 (+0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-03 2026-03-03/amc
Inst Owners99.82%
Inst Owner Change-2.37%
Ins Owners0.69%
Ins Owner Change10.39%
Market Cap1.80B
Revenue(TTM)134.48M
Net Income(TTM)-63.43M
Analysts84.44
Price Target24.62 (2.5%)
Short Float %10.28%
Short Ratio7.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)63.29%
Min EPS beat(2)20.62%
Max EPS beat(2)105.95%
EPS beat(4)3
Avg EPS beat(4)-13.1%
Min EPS beat(4)-206.99%
Max EPS beat(4)105.95%
EPS beat(8)6
Avg EPS beat(8)-2.48%
EPS beat(12)8
Avg EPS beat(12)-2.95%
EPS beat(16)12
Avg EPS beat(16)3.95%
Revenue beat(2)1
Avg Revenue beat(2)69.22%
Min Revenue beat(2)-8.1%
Max Revenue beat(2)146.55%
Revenue beat(4)2
Avg Revenue beat(4)33.61%
Min Revenue beat(4)-32.69%
Max Revenue beat(4)146.55%
Revenue beat(8)4
Avg Revenue beat(8)11.83%
Revenue beat(12)7
Avg Revenue beat(12)16.19%
Revenue beat(16)8
Avg Revenue beat(16)13.31%
PT rev (1m)9.43%
PT rev (3m)7.81%
EPS NQ rev (1m)-129.97%
EPS NQ rev (3m)-120.84%
EPS NY rev (1m)-3.95%
EPS NY rev (3m)44%
Revenue NQ rev (1m)-65.66%
Revenue NQ rev (3m)-63.48%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)37.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 182.41
P/S 13.37
P/FCF N/A
P/OCF N/A
P/B 5.62
P/tB 5.86
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)0.13
Fwd EY0.55%
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS1.8
BVpS4.28
TBVpS4.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.97%
ROE -19.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-9.25%
ROA(5y)-23.15%
ROE(3y)-12.18%
ROE(5y)-33.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.88%
Cap/Sales 1.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.94
Quick Ratio 6.94
Altman-Z 11.35
F-Score6
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)85.79%
Cap/Depr(5y)108.98%
Cap/Sales(3y)4.19%
Cap/Sales(5y)15.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y36.42%
EPS Next 2Y44.73%
EPS Next 3Y31.63%
EPS Next 5Y17.53%
Revenue 1Y (TTM)116.21%
Revenue growth 3Y41.91%
Revenue growth 5Y20.93%
Sales Q2Q%72.59%
Revenue Next Year66.87%
Revenue Next 2Y62.13%
Revenue Next 3Y33.15%
Revenue Next 5Y33.42%
EBIT growth 1Y41.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.75%
EBIT Next 3Y42.32%
EBIT Next 5YN/A
FCF growth 1Y-134.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-132.93%
OCF growth 3YN/A
OCF growth 5YN/A

ZYMEWORKS INC / ZYME FAQ

What is the ChartMill fundamental rating of ZYMEWORKS INC (ZYME) stock?

ChartMill assigns a fundamental rating of 5 / 10 to ZYME.


What is the valuation status for ZYME stock?

ChartMill assigns a valuation rating of 2 / 10 to ZYMEWORKS INC (ZYME). This can be considered as Overvalued.


Can you provide the profitability details for ZYMEWORKS INC?

ZYMEWORKS INC (ZYME) has a profitability rating of 2 / 10.


What is the expected EPS growth for ZYMEWORKS INC (ZYME) stock?

The Earnings per Share (EPS) of ZYMEWORKS INC (ZYME) is expected to grow by 36.42% in the next year.